Schizophrenic Disorders Clinical Trial
Official title:
A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
This study determined if a single dose of LY2140023 (pomaglumetad methionil) affects the electrical activity in the heart in participants with schizophrenia. This study also helped determine how a single high dose of LY2140023 is tolerated by participants.
The primary objective of this study was to determine that a single supratherapeutic dose of LY2140023 does not differ from placebo in the mean change from baseline in 12-lead electrocardiogram (ECG) QT interval measurements, such that the upper bound of the 2-sided 90% confidence interval (CI) for the greatest time-matched mean effect is <10 ms in subjects with schizophrenia. The secondary objective was to further evaluate the tolerability of a supratherapeutic single dose of LY2140023 monohydrate. Male or female subjects diagnosed with schizophrenia and aged between 18 and 65 years, inclusive, who had not been hospitalized for psychiatric illness for at least 12 weeks prior to Day 1 of the lead-in period, and who had a Clinical Global Impression - Severity scale score of <4 were included in the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04608032 -
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
|
N/A | |
| Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
| Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
| Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
| Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
| Completed |
NCT02525315 -
Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations
|
Phase 2 | |
| Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
| Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
| Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
| Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
| Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
| Active, not recruiting |
NCT00161408 -
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
|
N/A | |
| Terminated |
NCT05164289 -
Interest of EMDR Schizophrenic Disorders
|
||
| Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
| Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
| Completed |
NCT02544516 -
Upside Down, Give me the Handle
|
N/A | |
| Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |